Real-life analysis of neoadjuvant-therapy-associated benefits for pathological complete response and survival in early breast cancer patients - role of trastuzumab in HER2+ BC and platinum in TNBC.

Chung, Wei-Pang; Yang, Chun-Ting; Yang, Shuen-Ru; Su, Ching-Yen; Su, Hsin-Wei; Liu, Shang-Yun; Ou, Huang-Tz

Chung, Wei-Pang; Yang, Chun-Ting; Yang, Shuen-Ru; Su, Ching-Yen; Su, Hsin-Wei; Liu, Shang-Yun; Ou, Huang-Tz.

Afiliación

Chung WP; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Yang CT; Center of Applied Nanomedicine, National Cheng Kung University, Tainan, Taiwan.
Yang SR; Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Su CY; Department of Oncology, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Su HW; Medical Division, Roche Products Ltd., Taipei, Taiwan.
Liu SY; Medical Division, Roche Products Ltd., Taipei, Taiwan.
Ou HT; Medical Division, Roche Products Ltd., Taipei, Taiwan.

Front Oncol ; 12: 1022994, 2022.

Article en En | MEDLINE | ID: mdl-36761415

Palabras clave

HER2-positive breast cancer; early breast cancer; neoadjuvant therapy; platinum; trastuzumab; triple-negative breast cancer

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Tipo de estudio: Risk_factors_studies Idioma: En Revista: Front Oncol Año: 2022 Tipo del documento: Article País de afiliación: Taiwán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google